Publications

The references below are to peer-reviewed publications either related to the technology platforms of Caladrius Biosciences or authored/co-authored by Caladrius Biosciences.

T Regulatory Cell Technology

Marek-Trzonkowsa, N., et al. (2016.) Factors affecting long-term efficacy of T regulatory cell-based therapy in type 1 diabetes, 14 (332). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5131539/

Bluestone, J., et al. (2015.) Type 1 Diabetes Immunotherapy Using Polyclonal Regulatory T Cells. Science Translational Medicine, 7 (315). http://stm.sciencemag.org/content/7/315/315ra189

Marek-Trzonkowsa, N., et al. (2014.) Therapy of Type 1 Diabetes with CD4(+)CD25(high)CD127- Regulatory T Cells Prolongs Survival of Pancreatic Islets – Results of One Year Follow-up. Clin Immunol.153(1):23-30. http://www.ncbi.nlm.nih.gov/pubmed/24704576 

Marek-Trzonkowska, N., et al. (2012.) Administration of CD4+CD25highCD127- Regulatory T Cells Preserves Beta-cell Function in Type 1 Diabetes in Children. Diabetes Care, 35(9): 1817-20. http://care.diabetesjournals.org/content/35/9/1817.long

Brunstein, C.G., et al. (2011.) Infusion of Ex Vivo Expanded T Regulatory Cells in Adults Transplanted with Umbilical Cord Blood: Safety Profile and Detection Kinetics. Blood, 117(3): 1061-70. http://www.bloodjournal.org/content/117/3/1061.long?sso-checked=true

Hippen, K.L., et al. (2011.) Massive Ex Vivo Expansion of Human Natural Regulatory T Cells (T(regs)) with Minimal Loss of In Vivo Functional Activity. Sci Transl Med, 3(83): 83-83. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551476/

Tang, Q. and J.A. Bluestone, (2008.) The Foxp3+ Regulatory T Cell: A Jack of All Trades, Master of Regulation. Nat Immunol, 9(3): 239-44. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3075612/

Tang, Q., et al. (2004.) In Vitro-expanded Antigen-specific Regulatory T Cells Suppress Autoimmune Diabetes. J Exp Med, 199(11): 1455-65. http://jem.rupress.org/content/199/11/1455.long

 


CD34 Cell Technology

Quyyumi A., et al. (2016.) PreSERVE-AMI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Intracoronary Administration of Autologous CD34+ Cells in Patients with Left Ventricular Dysfunction Post STEMI. Circulation Research, 119(10). http://circres.ahajournals.org/content/early/2016/11/07/CIRCRESAHA.115.308165

Fujita, Y., et al. (2014.) Phase II Clinical Trial of CD34+ Cell Therapy to Explore Endpoint Selection and Timing in Patients with Critical Limb Ischemia. Circulation Journal, 78(2): 490- 501. https://www.jstage.jst.go.jp/article/circj/78/2/78_CJ-13-0864/_article

Assmus, B.,  et al. (2014.) Long-term Clinical Outcome after Intracoronary Application of Bone Marrow-derived Mononuclear Cells for Acute Myocardial Infarction: Migratory Capacity of Administered Cells Determines Event-free Survival. European Heart Journal, 35(19):1275-83. http://eurheartj.oxfordjournals.org/content/35/19/1275.long

Delewi, R., et al. (2014.) Impact of Intracoronary Bone Marrow Cell Therapy on Left Ventricular Function in the Setting of ST-segment Elevation Myocardial Infarction: A Collaborative Meta-analysis. European Heart Journal, 35(15):989-98. http://eurheartj.oxfordjournals.org/content/35/15/989.long

Losordo, D., et al. (2012.) A Randomized, Controlled Pilot Study of Autologous CD34+ Cell Therapy for Critical Limb Ischemia. Circ Cardiovasc Interv, 5 (6): 821-30.  http://circinterventions.ahajournals.org/content/5/6/821.long

Delewi, R., et al. (2012). Impact of Intracoronary Cell Therapy on Left Ventricular Function in the Setting of Acute Myocardial Infarction: A Meta-analysis of Randomized Controlled Clinical Trials. Heart (British Cardiac Society). http://www.ncbi.nlm.nih.gov/pubmed/22875736

Zimmet, H., et al. (2012.) Short- and Long-term Outcomes of Intracoronary and Endogenously Mobilized Bone Marrow Stem Cells in the Treatment of ST-segment Elevation Myocardial Infarction: A Meta-analysis of Randomized Control Trials. European Journal of Heart Failure, 14(1), 91–105. http://onlinelibrary.wiley.com/doi/10.1093/eurjhf/hfr148/full

Kinoshita, M., et al. (2012.) Long-term Clinical Outcome after Intramuscular Transplantation of Granulocyte Colony Stimulating Factor-mobilized CD34 Positive Cells in Patients with Critical Limb Ischemia.  Atherosclerosis, 224(2): 440-45. http://www.atherosclerosis-journal.com/article/S0021-9150(12)00503-5/abstract

Kawamoto, A., et al. (2009.) Intramuscular Transplantation of G-CSF-mobilized CD34(+) Cells in Patients with Critical Limb Ischemia: A Phase I/IIa, Multicenter, Single-blinded, Dose-escalation Clinical Trial. Stem Cells, 27 (11), 2857-64. http://onlinelibrary.wiley.com/doi/10.1002/stem.207/abstract

Schächinger, V., et al. (2006.) Improved Clinical Outcome after Intracoronary Administration of Bone-marrow-derived Progenitor Cells in Acute Myocardial Infarction: Final 1-year Results of the REPAIR-AMI Trial. European Heart Journal, 27(23), 2775–83. http://eurheartj.oxfordjournals.org/content/ehj/27/23/2775.full.pdf


Tumor Cell / Dendritic Cell Technology

Dillman, R., et al. (2015.) Superiority in a Randomized Trial of Patient-Specific Dendritic Cell/Tumor Cell Vaccines Vs Tumor Cell Vaccines in Subsets Defined by Disease Stage, Tumor Measurability, and Lactate Dehydrogenase (LDH) Level. Poster presented at: Society for Melanoma Research 2015 Congress; November 2015. San Francisco, CA. http://clbs.bio/1OhEf7q

Nistor, G., et al. (2015.) Mechanism of Action of CLBS20: A Patient-Specific Immunotherapy Targeting Metastatic Melanoma. Poster presented at: Society for Melanoma Research 2015 Congress; November 2015. San Francisco, CA. http://clbs.bio/1OhEf7q

Dillman, R., et al. (2015.) Superiority of Dendritic Cell Vaccine Vs Tumor Cell Vaccine: Survival by Stratification Subsets in MACVAC Randomized Phase II Trial of Patient-Specific Vaccines Utilizing Antigens from Autologous Melanoma Tumor Cell Lines. Poster presented at: The Society for Immunotherapy of Cancer 30th Anniversary Annual Meeting & Associated Programs; November 2015; National Harbor, MD. http://clbs.bio/1lwITFe

Nistor, G., et al. (2015.) Functional Properties of Patient-Derived Melanoma Cancer Stem Cells. Poster presented at: The Society for Immunotherapy of Cancer 30th Anniversary Annual Meeting & Associated Programs; November 2015; National Harbor, MD. http://clbs.bio/1HZtyqw

Dillman, R., et al. (2015.) Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at the Time of Treatment. Cancer Biotherapy and Radiopharmaceuticals, 30(5): 187-94 . http://online.liebertpub.com/doi/pdfplus/10.1089/cbr.2015.1843

Dillman, R., et al. (2015.) Cancer Vaccines: Can They Improve Survival? Cancer Biotherapy and Radiopharmaceuticals, 30(4): 147-51 . http://online.liebertpub.com/doi/full/10.1089/cbr.2014.1805

Dillman, R. (2015.) Patient-specific therapeutic vaccines for metastatic melanoma. Oncology issues, March/April 48-57. http://www.nxtbook.com/nxtbooks/accc/oncologyissues_20150304/index.php?startid=48

Bayer, M., et al. (2014.) Phase I Trial of Active Specific Immunotherapy with Autologous Dendritic Cells Pulsed with Autologous Irradiated Tumor Stem Cells in Hepatitis B Positive Patients with Hepatocellular Carcinoma. J Surg Oncol, 111(7): 862-67. http://onlinelibrary.wiley.com/doi/10.1002/jso.23897/full

Dillman, R., A. Cornforth, and C. DePriest. (2013.) Cancer Stem Cell Antigens from Autologous Tumor Cell Lines in Patient-Specific Active Immunotherapy for Metastatic Cancer, Stem Cell and Cancer Stem Cells, 9: 271-84. http://link.springer.com/chapter/10.1007%2F978-94-007-5645-8_26

Dillman, R., A. Cornforth, and G. Nistor. (2013.) Cancer Stem Cell Antigen-based Vaccines: The Preferred Strategy for Active Specific Immunotherapy of Metastatic Melanoma? Expert Opin Biol Ther, 13(5): 643-56. http://www.ncbi.nlm.nih.gov/pubmed/23451922

Dillman, R., et al. (2012.) Tumor Stem Cell Antigens as Consolidative Active Specific Immunotherapy: A Randomized Phase II Trial of Dendritic Cells Versus Tumor Cells in Patients with Metastatic Melanoma. J Immunother, 35(8): 641-49. http://www.ncbi.nlm.nih.gov/pubmed/22996370

Dillman, R., et al. (2010.) Durable Complete Response of Refractory, Progressing Metastatic Melanoma after Treatment with a Patient-specific Vaccine. Cancer Biother Radiopharm, 25(5): 553-57. http://online.liebertpub.com/doi/pdf/10.1089/cbr.2010.0819

Dillman R., (2009.) Whole Tumor Cell Vaccine Therapy in the Treatment of Patients with NSCLC. Symposium on Immunotherapy for the Treatment of Non-Small Cell Lung Cancer, 13th Annual International Lung Cancer Congress.

Dillman, R., et al. (2009.) Phase II Trial of Dendritic Cells Loaded with Antigens from Self-renewing, Proliferating Autologous Tumor Cells as Patient-specific Antitumor Vaccines in Patients with Metastatic Melanoma: Final Report. Cancer Biother Radiopharm, 24(3): 311-19. http://online.liebertpub.com/doi/pdf/10.1089/cbr.2008.0599

Dillman, R., S.K. Nayak, and L. Beutel. (1993.) Establishing In Vitro Cultures of Autologous Tumor Cells for Use in Active Specific Immunotherapy. Journal of Immunotherapy, 14(1): 65-69. http://journals.lww.com/immunotherapy-journal/Abstract/1993/07000/Establishing_In_Vitro_Cultures_of_Autologous_Tumor.9.aspx


Commentary

Preti, R., (2015.) Guest Commentary: Building a Problem or a Solution? Drug Discovery News. http://ddn-news.com/news?newsarticle=9878

Sietsema W, Wekselman K. (2015.) Agency Meetings with the US Food and Drug Administration. Regulatory Focus. Regulatory Affairs Professionals Society. http://www.raps.org/Regulatory-Focus/Features/2015/06/09/22643/Agency-Meetings-with-the-US-Food-and-Drug-Administration/